OncoMatch/Clinical Trials/NCT04895020
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Is NCT04895020 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies 9-valent HPV vaccine for hpv infections.
Treatment: 9-valent HPV vaccine — This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Prior therapy
Cannot have received: HPV vaccine
Received marketed HPV vaccine or plan to receive marketed HPV vaccine during this study period or have enrolled in HPV vaccine clinical trials
Cannot have received: immunosuppressive treatment (long-term glucocorticoid use (≥2mg per kg per day, lasted more than two wks))
received immunosuppressive treatment within one month before study such as long-term glucocorticoid use(≥2mg per kg per day, lasted more than two wks), or plan to receive such treatment from day 0 to month 7 after the last dose
Cannot have received: inactivated or recombinant vaccines
Receipt of inactivated or recombinant vaccines within 14 days
Cannot have received: live vaccines
live vaccines within 28 days
Cannot have received: immune globulin or blood-related products
Receipt of immune globulin or blood-related products within 3 months; or plan to receive such products during this study period
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify